Skip to main content

Table 2 Recent studies concerning CPAP and surfactant administration

From: Exogenous surfactant therapy in 2013: what is next? who, when and how should we treat newborn infants in the future?

Study (ref)

Year

N

Population

Outcome

Groups

COIN Trial (78)

2008

610

25-28 wks

 

CPAP

Systematic intubation

    

Death or BPD

33.9%

38.9%

    

Intubation

46%

100%

    

Selective surfactant

38%***

77%

    

Pneumothorax

9%***

3%

Rojas et al. (79)

2009

279

27-31 wks

 

CPAP

Intubation-early surfactant-extubation

    

Need for MV

39%*

26%

    

Pneumothorax

9%

2%

    

Rescue surfactant

26%**

12%

    

BPD at 36 wks PMA

59%

49%

CURPAP Trial (80)

2010

208

25-28 wks

 

CPAP Early selective Surfactant

Prophylactic surfactant

    

Need for MV

33%

31.4%

    

Death at 36 wks PMA

10.7%

8.6%

    

Pneumothorax

1%

6.7%

    

BPD

11.7%

14.3%

SUPPORT Trial (81)

2010

1316

24-28 wks

 

CPAP

Intubation-early surfactant use

    

Death or BPD

48.7%

54.1%

    

Surfactant use

67.1%***

98.9%

    

Air leak

6.8%

7.4%

Dunn et al. (82)

2011

648

26-29 wks

 

CPAP Selective surfactant

Prophylactic surfactant

Intubation-early surfactant-extubation

    

Surfactant use

14.8%***

98.6%

98.2%

    

Death or BPD

30.5%

36.5%

28.5%

    

Pneumothorax

5.4%

4.8%

3.2%

  1. BPD=bronchopulmonary dysplasia, PMA=postmenstrual age, MV=mechanical ventilation; wks: weeks of gestation.
  2. *:p<0.05; **:p<0.01; ***:p<0.001.